Physician profile
David C Yi
NPI 1700899044
$7,953.86
in general payments reported to CMS, 2019-2025
55 companies · $972 in 2025
The $972 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $1,096 · 2021: $1,045 · 2022: $911 · 2023: $1,493 · 2024: $1,487 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,877 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.18 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,222.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $673.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $642.34 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $512.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $361.61 | 2019-2025 | Xyosted |
| Lilly USA, LLC | $323.76 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $323.27 | 2019-2025 | |
| Amarin Pharma, INC. | $255.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.86 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $238.04 | 2021-2024 | |
| Tris Pharma INC | $236.93 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Otsuka America Pharmaceutical, INC. | $223.49 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $195.08 | 2019-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $180.29 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $168.52 | 2019-2021 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $154.40 | 2019-2023 | |
| Allergan, INC. | $129.55 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $122.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.52 | 2019-2022 | |
| Neos Therapeutics, LP | $118.57 | 2019-2022 | |
| Genentech USA, INC. | $112.25 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.79 | 2022 | |
| Amgen INC. | $95.90 | 2019-2025 | Repatha, Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $95.04 | 2020-2025 | Zoryve, Seglentis, Livalo |
| Exact Sciences Corporation | $93.11 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $75.00 | 2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.70 | 2019-2024 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $65.71 | 2023 | Auvelity, Sunosi |
| Eisai INC. | $59.96 | 2019-2021 | |
| Lundbeck LLC | $49.43 | 2025 | Vyepti |
| Merck Sharp & Dohme LLC | $49.30 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi Pasteur INC. | $48.67 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $44.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $42.33 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $38.12 | 2023 | Trudhesa |
| Dexcom, INC. | $37.61 | 2024 | Dexcom G6 Transmitter |
| Lupin INC. | $35.01 | 2019 | |
| Tolmar, INC. | $34.90 | 2025 | Jatenzo |
| Ibsa Pharma INC. | $34.73 | 2019-2025 | Tirosint, Licart, Flector |
| Clarus Therapeutics INC. | $33.56 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.62 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $27.94 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.95 | 2023 | Jornay Pm |
| Acella Pharmaceuticals, LLC | $23.17 | 2024 | NP Thyroid 60 |
| Abbott Laboratories | $22.64 | 2023 | Freestyle Libre 2 |
| Inspire Medical Systems, INC. | $20.28 | 2025 | Inspire |
| Therapeuticsmd, INC. | $19.77 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.44 | 2022 | Xyosted, Tlando |
| Bausch Health US, LLC | $18.25 | 2022 | |
| Halozyme INC | $17.85 | 2023 | |
| Seqirus USA INC | $16.82 | 2022 | |
| Medtronic, INC. | $15.33 | 2024 | Intellis Adaptivestim |
| Adlon Therapeutics L.P. | $14.74 | 2021 | |
| Optos, INC. | $12.99 | 2022 | |
| Aytu Biopharma, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.